CLEVELAND, Sept. 9, 2016 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company has received China Food and Drug Administration (CFDA) approval for its MRIdian System, the world’s first and only clinical MRI-guided radiation therapy system.
The MRIdian system is a unique medical instrument that integrates full-time MR imaging, cobalt radiation delivery, and intelligent software automation to treat cancers throughout the body. Using the MRIdian system, clinicians can see soft tissue, and visualize and adjust the dose all in real time, on live anatomy. With MRIdian this is done without exposing the patient to the additional ionizing radiation that is common with other imaging modalities.
“China is one of the largest markets for medical devices in the world, so securing CFDA approval is an important step in our growth strategy,” said Chris A. Raanes, president and chief executive officer of ViewRay. “Given its population and rising cancer incidence, we believe MRI-guided radiation therapy will be an important cancer fighting tool for doctors and their patients throughout China.”
ViewRay is represented in China by Cowealth Medical Holding Co.
“We’re pleased to partner with ViewRay to bring the benefits of MRIdian to China,” said Duane Lee, president and chief executive officer of Cowealth. “We believe MRI-guided radiation therapy is an essential advancement in radiation oncology and look forward to helping expand access to this vital treatment option.”
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the rate of cancer incidence in China’s population, the benefits of the MRIdian System for physicians and patients in China and the expected reception of the MRIdian System in China. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/viewray-receives-chinese-regulatory-approval-for-its-mridian-system-300325414.html
SOURCE ViewRay, Inc.
